Servier buys Edgewise muscular dystrophy business in $2.65B deal

Servier is buying Edgewise Therapeutics’ muscular dystrophy business in a deal worth up to $2.65 billion, adding late-stage candidate sevasemten and the associated team and capabilities to its rare neurology portfolio. The companies said June 1, 2026, that the transaction includes $1.55 billion upfront and up to $1.1 billion in regulatory and commercial milestones, with closing expected in the third quarter of 2026, subject to regulatory clearance and customary conditions. Sevasemten is being studied in a pivotal Becker muscular dystrophy cohort and a phase 2 Duchenne muscular dystrophy program, making it the centerpiece of the acquisition. (servier.com)

Why it matters: For veterinary professionals, this is mostly a signal story rather than a practice-changing one. The deal shows continued investor and pharma interest in rare neuromuscular disease, especially platforms built around muscle preservation rather than gene replacement. It also underscores how positive mid- to late-stage data can quickly reshape a biotech’s strategy: Edgewise had been positioning sevasemten as a potential first approved therapy for Becker muscular dystrophy, while continuing to advance separate cardiovascular assets that it can now prioritize after the sale. (nasdaq.com)

What to watch: Watch for deal close in Q3 2026, top-line GRAND CANYON data in Becker in 4Q 2026, and whether Servier keeps Edgewise’s previously outlined plan for a U.S. filing in the first half of 2027. (servier.com)